



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Plot No. 109-D, Road No. 29, Sion (East),
Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.: L37060MH1984PLC055433

Ref: ADL/SE/2025-26/05
April 29, 2025

To,
Listing/ Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001

BSE CODE – 524348

To,
Listing/ Compliance Department
National Stock Exchange of India Limited,
“Exchange Plaza”, Bandra - Kurla Complex,
Bandra (E), Mumbai – 400051

NSE SYMBOL: AARTIDRUGS

Dear Sir/Madam,

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sub: Intimation of Conference Call

This is to inform you that Quarterly Earning Conference Call for the Investors and Analysts have been scheduled on **May 7, 2025 at 11:00 A.M. IST** to discuss the Company's financial performance for the Quarter ended March 31, 2025.

Please find attached herewith invitation for the same.

Kindly take the same on record.

Thanking you,

Yours faithfully,

FOR AARTI DRUGS LIMITED

RUSHIKESH DEOLE
COMPANY SECRETARY & COMPLIANCE OFFICER
ICSI M.No.: F12932



Aarti Drugs Ltd.

Q4 FY25 Earnings Conference Call

DATE & TIME

7th May 2025 (Wednesday) 11:00 am, IST

(HK/Singapore 1:30 pm, UK 6:30 am, USA 01:30 am EST)

PARTICIPANTS

Mr. Harshit Savla – Jt. Managing Director

Mr. Harit Shah – Whole time Director

Mr. Adhish Patil – Chief Finance Officer & Chief Operating Officer

Mr. Vishwa Savla – Managing Director, Pinnacle Life Science Private Limited

PRE REGISTRATION LINK – [CLICK HERE](#)

CONFERENCE DIAL IN DETAILS

INDIA	+91 22 6280 1309 / +91 22 7115 8210
UNITED STATES	1 866 746 2133
UNITED KINGDOM	0 808 101 1573
SINGAPORE	800 101 2045
HONG KONG	800 964 448

RSVP:

Strategic Growth Advisors Pvt. Ltd.

Mr. Deven Dhruva

Contact: +91 98333 73300